Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Has announcements × Pemetrexed × Clear all

Phase

Phase 3 22 Phase 2/3 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 2 nilotinib 2 avapritinib 2 trastuzumab deruxtecan 1 talquetamab 1 pomalidomide 1 montelukast 1 lazertinib 1 larotrectinib 1 ivosidenib 1 entrectinib 1 dostarlimab 1 daratumumab 1 carfilzomib 1 asciminib 1 amivantamab 1 Thalidomide 1 TIC10 compound 1 Prednisone 1 Pemetrexed 1 Melphalan 1 Lenalidomide 1 Imatinib Mesylate 1 Diphenhydramine 1 Dexamethasone 1 Dasatinib 1 Crizotinib 1 Carboplatin 1 Bortezomib 1 Appointments and Schedules 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02609776 2026-04-13

CHRYSALIS

Janssen Research & Development, LLC

Phase 1 Active not recruiting

751 enrolled 2 FDA

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡